Dato’ Dr. Suhaini Kadiman,
Director of Clinical Research
Clinical research in cardiovascular was and still remains one of the core objectives of the Institut Jantung Negara (IJN) since its inception in 1992. We are most dedicated to the treatment of cardiovascular disease and conscious for the need of research in this area. In line with national direction to promote clinical trial programs in this region, IJN has aspired to be the key player giving a full commitment and take a lead to accelerate and foster the clinical research agenda, in particular cardiovascular diseases in this region.
We have a number of collaboration research programs with local and international universities as a strategic approach to promote, encourage and bring cardiovascular research in IJN to a higher level. Through emphasizing observational studies and involvement in internationally recognized clinical trial activities, research agenda in IJN has continued to grow and produce interesting results. Our capacity to design, implement and coordinate a large number of clinical research has continued to improve and our contribution to the national community is now more recognized and aligned with national direction to establish clinical trial hubs in this region. Together with scientists and researchers from other academics and research institutes, IJN plays a leading role in these advances.
Our clinicians have been involved in most international conferences and scientific meeting that provide forum to highlight our recent research outcomes and serve as a platform to present their research works as well as encourage stimulating discussions and sharing knowledge among peers and colleagues. Our experiences and accomplishments have been expanded into full scientific papers that published in a number of regional and international medical journals with exceptional impact factors.
With increasing maturity, experience and networking with industry, we have eventually embarked into industry-sponsored (ISRs) programs as well. Most of the Clinical Research Organization (CRO) and pharmaceutical industries have recognized the commitment of IJN in making the success of clinical trial program in cardiovascular diseases.
In priorities the need for our research agenda, we continue develop and culminate research culture amongst our clinicians with relevant support and equivalent opportunities. This is calling for the development of capacities and capabilities in term of infrastructure and creation of specialized pools of clinical investigators to undertake the ISRs. There will be a demand for GCP trained clinical investigators, thus, there is a bright future for institute which can provide clinical research professional in order to meet the growing demands of skilled manpower by the industry.
